{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT05682144",
      "orgStudyIdInfo": {
        "id": "MT2021-24"
      },
      "organization": {
        "fullName": "Immusoft of CA, Inc.",
        "class": "INDUSTRY"
      },
      "briefTitle": "ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I",
      "officialTitle": "A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Adult Patients With Mucopolysaccharidosis Type I Hurler-Scheie and Scheie"
    },
    "statusModule": {
      "statusVerifiedDate": "2025-04",
      "overallStatus": "RECRUITING",
      "startDateStruct": {
        "date": "2023-04-12",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2025-06-01",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2039-06-01",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2022-12-12",
      "studyFirstSubmitQcDate": "2023-01-03",
      "studyFirstPostDateStruct": {
        "date": "2023-01-12",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2025-04-28",
      "lastUpdatePostDateStruct": {
        "date": "2025-04-30",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Immusoft of CA, Inc.",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": true,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "A first-in-human study using ISP-001 in adult patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie.",
      "detailedDescription": "This is a Phase 1, first-in-human, open-label, single-arm study in which adult patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie are treated with autologous plasmablasts engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty transposon system (ISP-001). This study will evaluate the safety and tolerability of ISP-001."
    },
    "conditionsModule": {
      "conditions": [
        "Mucopolysaccharidosis IH/S",
        "Mucopolysaccharidosis IS"
      ],
      "keywords": [
        "MPS IH/S",
        "MPS IS"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "NA",
        "interventionModel": "SINGLE_GROUP",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 2,
        "type": "ESTIMATED"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Autologous Plasmablasts (B cells)",
          "type": "EXPERIMENTAL",
          "description": "Dose Level: 5 x 10e7 cells/kg on Day 0",
          "interventionNames": [
            "Biological: Autologous Plasmablasts (B cells)"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "Autologous Plasmablasts (B cells)",
          "description": "Autologous plasmablasts (B cells) engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty (SB) transposon system.",
          "armGroupLabels": [
            "Autologous Plasmablasts (B cells)"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Number of participants with treatment-related adverse events and serious adverse events",
          "description": "Incidence of Adverse Events as assessed by CTCAE (v 5.0)",
          "timeFrame": "24 Weeks"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Number of participants with treatment-related adverse events and serious adverse events",
          "description": "Incidence of Adverse Events as assessed by CTCAE (v 5.0)",
          "timeFrame": "48 Weeks"
        },
        {
          "measure": "Determination of Absolute Numbers of B and T cell populations",
          "description": "Determination of Absolute Numbers of B and T cell populations in peripheral blood at baseline and at scheduled time points post infusion.",
          "timeFrame": "1Year"
        },
        {
          "measure": "Concentration of IDUA",
          "description": "Determine IDUA concentration in plasma at baseline and at scheduled time points post infusion.",
          "timeFrame": "1 Year"
        },
        {
          "measure": "Assessment of Storage Material (glycosaminoglycan, or GAG)",
          "description": "Assessment of Storage Material (glycosaminoglycan, or GAG) in urine at baseline and at scheduled time points post infusion.",
          "timeFrame": "1 Year"
        },
        {
          "measure": "Levels of Circulating Antibodies (IgG, IgM, IgA, and IgE)",
          "description": "Determine levels of circulating antibodies (IgG, IgM, IgA, and IgE) at baseline and at scheduled time points post infusion.",
          "timeFrame": "1 Year"
        },
        {
          "measure": "Analysis of PBMCs",
          "description": "PBMCs will be analyzed at baseline and at scheduled time points post infusion.",
          "timeFrame": "1 Year"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of Mucopolysaccharidosis type I Hurler-Scheie or Scheie syndrome.\n* Age ≥ 18 years at time of study registration.\n* Creatinine clearance, calculated or measured directly, that is \\>60ml/min/1.73m2.\n* Ejection fraction ≥ 40% by echocardiogram.\n* Must commit to traveling to the study site for the necessary follow-up evaluations.\n* Must agree to stay \\<45-minute drive from the study site for a minimum of 5 days after cell infusion.\n\nExclusion Criteria:\n\n* Known familial inherited cancer syndrome. Suspected cases will be investigated, per the physicians discretion, using relevant genetic tests to determine presence of germline mutations.\n* History of B cell related cancer, EBV lymphoproliferative disease or autoimmune disorders.\n* Evidence of active graft-vs-host disease.\n* Underwent a previous hematopoietic stem cell transplant (HSCT).\n* Requirement for systemic immune suppression.\n* Requirement for continuous supplemental oxygen.\n* Any medical condition likely to interfere with assessment of safety or efficacy of the study treatment.\n* In the investigator's judgement, the subject is unlikely to complete all protocol-required study visits or procedures, including follow up visits, or comply with the study requirements for participation.\n\nOther protocol defined inclusion/exclusion criteria may apply.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "centralContacts": [
        {
          "name": "Jake Wesley, PharmD, MS",
          "role": "CONTACT",
          "email": "jake.wesley@immusoft.com"
        }
      ],
      "overallOfficials": [
        {
          "name": "Immusoft Clinical Development",
          "affiliation": "Immusoft of CA, Inc.",
          "role": "STUDY_DIRECTOR"
        }
      ],
      "locations": [
        {
          "facility": "UCSF Benioff Children's Hospital Oakland",
          "status": "RECRUITING",
          "city": "Oakland",
          "state": "California",
          "zip": "94609",
          "country": "United States",
          "contacts": [
            {
              "name": "Matt Thura",
              "role": "CONTACT",
              "email": "matt.thura@ucsf.edu"
            },
            {
              "name": "Paul Harmatz, MD",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "geoPoint": {
            "lat": 37.80437,
            "lon": -122.2708
          }
        },
        {
          "facility": "University of Minnesota",
          "status": "RECRUITING",
          "city": "Minneapolis",
          "state": "Minnesota",
          "zip": "55455",
          "country": "United States",
          "contacts": [
            {
              "name": "Paul Orchard, MD",
              "role": "PRINCIPAL_INVESTIGATOR"
            }
          ],
          "geoPoint": {
            "lat": 44.97997,
            "lon": -93.26384
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D008059",
          "term": "Mucopolysaccharidosis I"
        }
      ],
      "ancestors": [
        {
          "id": "D009083",
          "term": "Mucopolysaccharidoses"
        },
        {
          "id": "D002239",
          "term": "Carbohydrate Metabolism, Inborn Errors"
        },
        {
          "id": "D008661",
          "term": "Metabolism, Inborn Errors"
        },
        {
          "id": "D030342",
          "term": "Genetic Diseases, Inborn"
        },
        {
          "id": "D009358",
          "term": "Congenital, Hereditary, and Neonatal Diseases and Abnormalities"
        },
        {
          "id": "D016464",
          "term": "Lysosomal Storage Diseases"
        },
        {
          "id": "D017520",
          "term": "Mucinoses"
        },
        {
          "id": "D003240",
          "term": "Connective Tissue Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        },
        {
          "id": "D008659",
          "term": "Metabolic Diseases"
        },
        {
          "id": "D009750",
          "term": "Nutritional and Metabolic Diseases"
        }
      ]
    }
  },
  "hasResults": false
}